Hims & Hers Health Issues $402.5M in 0.00% Convertible Notes at 22.57% Premium
HIMS sits 75% above its 52-week low of $13.74.
Summary
Hims & Hers Health issued $402.5 million in 0.00% Convertible Senior Notes due 2032, priced at a 22.57% premium to the current stock price, and entered into capped call transactions to mitigate dilution.
Key Events · Financing and Capital Events · HIMS
-
Convertible Notes Issued
The company issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This includes the full exercise of the initial purchasers' option for an additional $52.5 million, finalizing the offering previously priced on May 19, 2026.
-
Favorable Conversion Terms
The notes bear 0.00% interest, meaning no cash interest payments. The initial conversion price is approximately $29.53 per share, representing a 22.57% premium over the current stock price of $24.09.
-
Dilution Mitigation with Capped Calls
Hims & Hers Health entered into capped call transactions for approximately $36.7 million. These are designed to reduce potential dilution to Class A common stock and/or offset cash payments upon conversion, with a cap price of approximately $50.15 per share.
-
Significant Capital Raise
The $402.5 million capital raise is substantial, representing approximately 7.35% of the company's current market capitalization, providing significant liquidity for general corporate purposes.
Analysis · HIMS · Industrial Applications And Services
Hims & Hers Health has finalized a substantial capital raise by issuing $402.5 million in 0.00% Convertible Senior Notes. This financing is significant due to its size and favorable terms, including no cash interest payments and a conversion price set at a notable premium to the current stock price. The accompanying capped call transactions further mitigate potential dilution for existing shareholders up to a higher price point. This capital infusion strengthens the company's financial position, providing resources for general corporate purposes and supporting its ongoing strategic initiatives, such as its expansion into GLP-1 weight-loss offerings, which has been a focus in recent months.
At the time of this filing, HIMS was trading at $24.09 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.